Kenvue Inc. (KVUE) Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the fiscal quarter ended March 30, 2025. Kenvue Inc. is a global consumer health company operating three segments: Self Care, Skin Health and Beauty, and Essential Health. The company operates independently following its separation from Johnson & Johnson (J&J) in 2023.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $3,741 million | $3,894 million |
| Gross Profit | $2,168 million | $2,242 million |
| Gross Margin | 58.0% | 57.6% |
| Operating Income | $558 million | $550 million |
| Net Income | $322 million | $296 million |
| Diluted EPS | $0.17 | $0.15 |
| Operating Cash Flow | $428 million | $287 million |
| Total Debt | $8,738 million | $8,607 million |
| Cash and Equivalents | $1,057 million | $1,155 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 3.9% year-over-year. Organic sales declined 1.2%, driven by a 0.9% volume decrease and 0.3% unfavorable value realization. Foreign currency headwinds contributed a 2.7% negative impact.
- Profitability Improvement: Despite lower sales, Net Income increased 8.8% to $322 million. Operating income rose 1.5% to $558 million, aided by the absence of a $68 million impairment charge recorded in Q1 2024 related to the former Skillman, NJ headquarters.
- Margin Expansion: Gross margin expanded 40 basis points to 58.0%, driven by supply chain optimization benefits, partially offset by volume deleverage and unfavorable value realization.
- Restructuring Costs: Restructuring expenses increased 46.3% to $60 million, primarily due to higher information technology and project-related costs under the "2024 Multi-Year Restructuring Initiative."
- Segment Performance:
- Self Care: Sales down 1.8%; Adjusted Operating Income down 5.8%.
- Skin Health and Beauty: Sales down 7.3%; Adjusted Operating Income down 37.0% due to competitive pressures and strategic price investments.
- Essential Health: Sales down 3.9%; Adjusted Operating Income down 9.5%.
Guidance, Outlook, and Risks
- Restructuring Outlook: The "2024 Multi-Year Restructuring Initiative" is expected to incur approximately $550 million in total pre-tax charges. The company expects to realize full annualized pre-tax gross cost savings of approximately $350 million beginning in fiscal year 2026.
- Tariff Exposure: Management estimates incremental gross tariff exposure of approximately $150 million for fiscal year 2025 due to new U.S. executive orders and retaliatory measures.
- Liquidity: The company maintains a $4.0 billion revolving credit facility (unused) and a $4.0 billion commercial paper program ($1.676 billion outstanding). Management believes cash flows and borrowing capacity are sufficient to meet obligations for the next 12 months.
- Legal Contingencies: Significant ongoing litigation includes:
- Acetaminophen (Tylenol): Claims alleging a link to autism/ADHD; cases dismissed in federal court but on appeal.
- Phenylephrine (PE): Class actions regarding FDA findings on efficacy; cases dismissed in federal court but on appeal.
- Talc: J&J retains liability for U.S. and Canada; Kenvue remains responsible for talc liabilities outside these regions.
- Zantac (Ranitidine): Indemnification disputes with Pfizer and Boehringer Ingelheim regarding NDMA contamination claims.
Investor Verification Checklist
- Verify the timeline and cost realization of the $550 million restructuring initiative versus the projected $350 million annualized savings.
- Monitor the status of appeals regarding the acetaminophen and phenylephrine litigation, as well as the potential for new filings.
- Assess the impact of the estimated $150 million tariff exposure on future gross margins and pricing strategies.
- Review the performance of the Skin Health and Beauty segment, which saw a significant 37% drop in adjusted operating income.
- Track the progress of the Deferred Local Business transfers from J&J, particularly in China, Malaysia, and Russia.